The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer
{{output}}
Background: Up to half of cancer patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAEs). However, the long-term consequences of irAEs remain poorly characterized. ... ...
